Acquired resistance to cancer immunotherapy
- 2 July 2018
- journal article
- review article
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 41 (1) , 31-40
Abstract
In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.Keywords
This publication has 100 references indexed in Scilit:
- Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancerBritish Journal of Cancer, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem CellsCancer Research, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cellsImmunology, 2003
- THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor SignalingAnnual Review of Immunology, 1997
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995